Search | IOVS | ARVO Journals

Showing 1 – 20 of 32

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina December 2024

Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema

PDF

David S. Boyer; Nathan C. Steinle; Joel A. Pearlman; Cameron M. Stone; Courtney Crawford; Sunil Gupta; Pravin U. Dugel; Megan E. Baldwin; Ian M. Leitch
TAGS: aflibercept, diabetic macular edema, vascular endothelial growth factor a, vascular endothelial growth factor c, vascular endothelial growth factors
Trans. Vis. Sci. Tech.. 2024; 13(12):32. https://doi.org/10.1167/tvst.13.12.32

Clinical Trials December 2021

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

PDF

Pravin U. Dugel; Arshad M. Khanani; Brian B. Berger; Sunil Patel; Mitchell Fineman; Glenn J. Jaffe; Petra Kozma-Wiebe; Jeffrey Heier
TAGS: diabetic macular edema, injections, plasma kallikrein, safety, inflammation, surrogate endpoints, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):28. https://doi.org/10.1167/tvst.10.14.28

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Disease Activity Assessments with Brolucizumab vs Aflibercept in Patients with nAMD in HAWK and HARRIER

Rishi P Singh; Robin Hamilton; Jeffrey S Heier; Carl Regillo; Mark C Gillies; Georges Weissgerber; Jahangir Alam; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1158.

ARVO Annual Meeting Abstract June 2020

Vessel Density and Caliber Discriminate between Normal Retina and Clinical Stages of Diabetic Retinopathy

Sam Kushner-Lenhoff; Kaitlin Kogachi; Melissa Mert; Zhongdi Chu; Neal V. Palejwala; Jeremy D Wolfe; Sujit Itty; Kimberly A Drenser; Antonio Capone; Pravin U Dugel; Andrew A Moshfeghi; Hossein Ameri; Ruikang K Wang; Amir H Kashani

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4107.

ARVO Annual Meeting Abstract July 2019

Assessing the Efficacy and Safety of Intravitreal Dexamethazone Implant in Treating Macular Edema in Eyes with an Incomplete Response to Anti-vascular Endothelial Growth Factor Agents.

Walid Abdallah; Mark Barakat; David Goldenberg; Sujit Itty; Pravin U Dugel; Karim Jamal; Derek Kunimoto; Sachin Mehta; Edward Quinlan; Neal Palejwala

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):98.

ARVO Annual Meeting Abstract July 2019

Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER

Rishi P Singh; Charles Clifton Wykoff; Ramin Tadayoni; Yuichiro Ogura; Adrian H C Koh; Frank G Holz; Robin Hamilton; David Tanzer; Georges Weissgerber; Jahangir Alam; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5194.

ARVO Annual Meeting Abstract July 2019

Treatment and Management of Neovascular AMD: Impact on Patients

Vincent W Li; Isaac R. Gabriel; Madeleine M Li; Andrew N Antoszyk; Carl W Baker; Pravin U Dugel; Roger A. Goldberg; Jeffrey S. Heier; Allen C Ho; John S Pollack; Charles Clifton Wykoff; Demetrios Vavvas; William W Li

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):136.

ARVO Annual Meeting Abstract July 2018

Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER

Pravin U Dugel; Gabriele Elisabeth Lang; Sam Razavi; Andreas Weichselberger; Yuichiro Ogura; David M Brown

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1455.

ARVO Annual Meeting Abstract July 2018

Comparative assessment of anatomical outcomes for nAMD patients treated with brolucizumab and aflibercept: 16-week data from the HAWK and HARRIER studies

Rishi P Singh; Andreas Weichselberger; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1464.

ARVO Annual Meeting Abstract July 2018

Quantitative assessment of changes in retinal vascular density and morphology among patients with diabetic retinopathy using spectral domain optical coherence tomography angiography (SD-OCTA)

Kaitlin Kogachi; TAI-CHI LIN; Neal V Palejwala; Sujit Itty; Jeremy D. Wolfe; Kimberly A Drenser; Antonio Jr. Capone; Pravin U Dugel; Xuejuan Jiang; Anoush Shahidzadeh; Zhongdi Chu; Ruikang K Wang; Amir H Kashani

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):739.

ARVO Annual Meeting Abstract July 2018

Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER

Glenn J Jaffe; Adrian H C Koh; Yuichiro Ogura; Andreas Weichselberger; Frank G. Holz; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1624.

ARVO Annual Meeting Abstract June 2017

3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration

Rafael Varona; Annaig Le-Halpere; Peter A Campochiaro; Jeffrey Heier; Pravin U Dugel; Mark Barsamian; Annie Purvis; Mario Cabrera-Salazar; Cheryl Delacono; Najwa Mostafa; Abraham Scaria; Ronald BUGGAGE

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2321.

ARVO Annual Meeting Abstract June 2017

Assessing the safety and efficacy of dexamethasone intraocular implant for macular edema after cataract surgery in patients with diabetes.

Neal Palejwala; Sravanthi Vegunta; Pravin U Dugel; Derek Kunimoto; karim jamal; David Goldenberg; Sachin Mehta; Edward Quinlan; Mark Barakat

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4620.

ARVO Annual Meeting Abstract June 2017

No Clear Benefit of Vitrectomy for Post-Injection Endophthalmitis in Age-Related Macular Degeneration

Mark Barakat; Neal Palejwala; Ashleigh L Levison; Sujit Itty; Milad Haak; Sachin Mehta; David Goldenberg; karim jamal; Edward Quinlan; Derek Kunimoto; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5499.

ARVO Annual Meeting Abstract June 2017

Quantitative spectral-domain optical coherence tomography angiography (OCTA) of Diabetic Retinopathy (DR) Severity

TAI-CHI LIN; Priyanka Gogte; Neal Palejwala; Anoush Shahidzadeh; Sujit Itty; Mark S Humayun; Andrew A Moshfeghi; Hossein Ameri; Zhongdi Chu; Ruikang K Wang; Jeremy D Wolfe; Pravin U Dugel; Amir H Kashani

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1653.

ARVO Annual Meeting Abstract June 2017

Persistent diabetic macular edema after 6 months of anti-VEGF therapy is associated with diminished long-term improvement in vision: a post-hoc analysis of Protocol I

Scott M Whitcup; Joanna Campbell; Anat Loewenstein; Pravin U Dugel; Nancy Holekamp; Szilard Kiss; Albert J Augustin; Vanessa Shih; Jeff Lai; Charles Clifton Wykoff; Srinivas R Sadda

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1906.

ARVO Annual Meeting Abstract September 2016

Consistency of visual acuity response to anti-VEGF therapy in diabetic macular edema patients: An analysis of DRCRnet Protocol I data

Scott M Whitcup; Joanna Campbell; Nancy Holekamp; Szilard Kiss; Anat Loewenstein; Albert J Augustin; Allen C Ho; Victor Gonzalez; Vanessa Shih; Amelia Orejudos; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

Real-World Assessment of Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Interim Analysis from the REINFORCE Study

Howard F Fine; Michael Singer; Pravin U Dugel; Antonio Capone, Jr.; John Maltman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3259.

ARVO Annual Meeting Abstract September 2016

A first in human study of Intravitreal (IVT) CLG561 in Subjects with Advanced Age-Related Macular Degeneration (AMD)

Louis C Glazer; Jonathan G. Williams; Carmelina M Gordon; Pravin U Dugel; Mark Milton; Thomas Valencia; Ulf Klein; Sandrine Kretz; Kinfemichael Gedif; Cynthia L Grosskreutz; Parisa Zamiri

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2672.

ARVO Annual Meeting Abstract September 2016

A 2-year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age-related macular degeneration: testing an alternative treatment regimen

Pravin U Dugel; James Warburton; Andreas Weichselberger; Peter Sallstig

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5018.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

Disease Activity Assessments with Brolucizumab vs Aflibercept in Patients with nAMD in HAWK and HARRIER

Vessel Density and Caliber Discriminate between Normal Retina and Clinical Stages of Diabetic Retinopathy

Assessing the Efficacy and Safety of Intravitreal Dexamethazone Implant in Treating Macular Edema in Eyes with an Incomplete Response to Anti-vascular Endothelial Growth Factor Agents.

Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER

Treatment and Management of Neovascular AMD: Impact on Patients

Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER

Comparative assessment of anatomical outcomes for nAMD patients treated with brolucizumab and aflibercept: 16-week data from the HAWK and HARRIER studies

Quantitative assessment of changes in retinal vascular density and morphology among patients with diabetic retinopathy using spectral domain optical coherence tomography angiography (SD-OCTA)

Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER

3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration

Assessing the safety and efficacy of dexamethasone intraocular implant for macular edema after cataract surgery in patients with diabetes.

No Clear Benefit of Vitrectomy for Post-Injection Endophthalmitis in Age-Related Macular Degeneration

Quantitative spectral-domain optical coherence tomography angiography (OCTA) of Diabetic Retinopathy (DR) Severity

Persistent diabetic macular edema after 6 months of anti-VEGF therapy is associated with diminished long-term improvement in vision: a post-hoc analysis of Protocol I

Consistency of visual acuity response to anti-VEGF therapy in diabetic macular edema patients: An analysis of DRCRnet Protocol I data

Real-World Assessment of Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Interim Analysis from the REINFORCE Study

A first in human study of Intravitreal (IVT) CLG561 in Subjects with Advanced Age-Related Macular Degeneration (AMD)

A 2-year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age-related macular degeneration: testing an alternative treatment regimen

To View More...

You must be signed into an individual account to use this feature.